

**RECORDATI: UPDATE ON THE EXECUTION OF THE SHARE BUY-BACK PROGRAM**

Milan, 15<sup>th</sup> January 2024 – Within the Recordati’s share buy-back program communicated to the market on 29<sup>th</sup> September 2023 and initiated on 2<sup>nd</sup> October 2023 , as per authorization granted by the Shareholders’ Meeting held on 21<sup>st</sup> April 2023, with the object of the servicing of current and future stock option / performance shares plans in favour of the Recordati Group’s management or share-based incentive plans that might be approved by the Company in the future, the Company communicates the following purchase transactions of Recordati shares pursuant to art. 2, paragraph 3, of the EU Delegated Regulation 2016/1052/EU, on the basis of the information provided by UBS Europe SE as intermediary in charge of executing, in full independency, the share buy-back program on behalf of the Company.

Aggregate details of daily transactions made from 8<sup>th</sup> to 12<sup>th</sup> January 2024 in Recordati ordinary shares (ISIN IT0003828271) are as follows:

SUMMARY OF PURCHASE TRANSACTIONS				
Date	Type of Transaction	Quantity	Weighted average price (Euro)	Exchange
08/01/2024	Purchase	1,054	47.7717	MTA
11/01/2024	Purchase	64	49.2266	MTA
<b>TOTAL</b>		<b>1,118</b>	<b>47.8550</b>	

The details of all the purchase transactions carried out in the period indicated above are reported in the following pages.

On 12<sup>th</sup> January 2024, the Company held no. 3,122,966 treasury shares which amount to 1.493% of the current share capital.

**Recordati** (Reuters RECI.MI, Bloomberg REC IM) is an international pharmaceutical group listed on the Italian Stock Exchange (ISIN IT 0003828271) uniquely structured to bring treatment across specialty and primary care, consumer healthcare, and rare diseases. We believe that health, and the opportunity to live life to the fullest, is a right, not a privilege. We want to support people in unlocking the full potential of their life. We have fully integrated operations across research & development, chemical and finished product manufacturing through to commercialisation and licensing. Established in 1926, Recordati operates in approximately 150 countries across EMEA, Americas and APAC regions. At the end of 2022, Recordati employed more than 4,300 people and consolidated revenue of € 1,853.3 million. For more information, please visit [www.recordati.com](http://www.recordati.com).

**RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.**

Registered Office  
Via Matteo Civitali, 1  
20148 Milano, Italy  
Tel. +39 02 487871  
Fax +39 02 40073747  
[www.recordati.com](http://www.recordati.com)

Share Capital € 26.140.644,50 fully paid-up  
Milano, Monza, Brianza and Lodi Comp. Reg. No. 00748210150  
Tax Code/VAT No. 00748210150  
Milano R.E.A. No. 401832

Company subject to the Management and Coordination Activity of Rossini Luxembourg S.à.r.l.

Attachment:  
Daily details of transactions

Date	Time (GMT)	Currency	Exchange	Price	Quantity
08/01/2024	08:09:32	EUR	MTA	47,7300	50
08/01/2024	08:09:32	EUR	MTA	47,7300	125
08/01/2024	08:50:29	EUR	MTA	47,8300	3
08/01/2024	08:50:29	EUR	MTA	47,8300	170
08/01/2024	09:02:08	EUR	MTA	47,7600	184
08/01/2024	09:25:55	EUR	MTA	47,7500	25
08/01/2024	09:25:55	EUR	MTA	47,7500	142
08/01/2024	09:57:59	EUR	MTA	47,7800	74
08/01/2024	09:57:59	EUR	MTA	47,7800	90
08/01/2024	10:00:00	EUR	MTA	47,7800	35
08/01/2024	10:00:00	EUR	MTA	47,7800	156
11/01/2024	16:03:40	EUR	MTA	49,2300	42
11/01/2024	16:03:56	EUR	MTA	49,2200	22